Epigenetic inactivation of miR-9 family microRNAs in chronic lymphocytic leukemia - Implications on constitutive activation of NFκB pathway

Molecular Cancer

Volumn 12, Issue 1, 2013, Pages

  Wang, Lu Q ^a   Kwong, Yok L ^a   Kho, Chi Shan B ^b   Wong, Kit F ^c   Wong, Kwan Y ^a   Ferracin, Manuela ^d   Calin, George A ^e   Chim, Chor S ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

^b PAMELA YOUDE NETHERSOLE EASTERN HOSPITAL   (Hong Kong)

^c QUEEN ELIZABETH HOSPITAL   (Hong Kong)

^d UNIVERSITY OF FERRARA   (Italy)

^e UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Chronic lymphocytic leukemia; DNA methylation; microRNA; miR 9 3; NF B; Tumor suppressor

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; CD19 ANTIGEN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MICRORNA 9;

ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; B LYMPHOCYTE; BONE MARROW; BONE MARROW BUFFY COAT; CELL PROLIFERATION; CELL VIABILITY; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; DNA METHYLATION; DOWN REGULATION; EPIGENETICS; HEMOGLOBIN BLOOD LEVEL; HUMAN; HUMAN CELL; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; PROMOTER REGION; RISK FACTOR; RNA METHYLATION; SIGNAL TRANSDUCTION; TUMOR CELL LINE; UPREGULATION;

ADULT; AGED; AGED, 80 AND OVER; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; DNA METHYLATION; EPIGENESIS, GENETIC; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; MICRORNAS; MIDDLE AGED; NF-KAPPA B; PROMOTER REGIONS, GENETIC; RETROSPECTIVE STUDIES; SIGNAL TRANSDUCTION;

EID: 84891000645     PISSN: None     EISSN: 14764598     Source Type: Journal    
DOI: 10.1186/1476-4598-12-173     Document Type: Article

References (49)

1. Esteller M. Epigenetics in cancer. N Engl J Med 2008, 358:1148-1159. 10.1056/NEJMra072067, 18337604.
2. Chim CS, Liang R, Kwong YL. Hypermethylation of gene promoters in hematological neoplasia. Hematol Oncol 2002, 20:167-176. 10.1002/hon.694, 12469326.
3. Jones PA, Baylin SB. The epigenomics of cancer. Cell 2007, 128:683-692. 10.1016/j.cell.2007.01.029, 17320506.
4. Gonzalez-Zulueta M, Bender CM, Yang AS, Nguyen TD, Beart RW, Van Tornout JM, Jones PA. Methylation of the 5′ CpG island of the p16/CDKN2 tumor suppressor gene in normal and transformed human tissues correlates with gene silencing. Cancer Res 1995, 55:4531-4535.
5. Chim CS, Pang R, Fung TK, Choi CL, Liang R. Epigenetic dysregulation of Wnt signaling pathway in multiple myeloma. Leukemia 2007, 21:2527-2536. 10.1038/sj.leu.2404939, 17882284.
6. Chim CS, Fung TK, Wong KF, Lau J, Liang R. Frequent DAP kinase but not p14 or Apaf-1 hypermethylation in B-cell chronic lymphocytic leukemia. J Hum Genet 2006, 51:832-838. 10.1007/s10038-006-0029-x, 16897188.
7. Raval A, Tanner SM, Byrd JC, Angerman EB, Perko JD, Chen S-S, Hackanson B, Grever MR, Lucas DM, Matkovic JJ, et al. Downregulation of Death-Associated Protein Kinase 1 (DAPK1) in Chronic Lymphocytic Leukemia. Cell 2007, 129:879-890. 10.1016/j.cell.2007.03.043, 17540169.
8. Chen SS, Claus R, Lucas DM, Yu L, Qian J, Ruppert AS, West DA, Williams KE, Johnson AJ, Sablitzky F. Silencing of the inhibitor of DNA binding protein 4 (ID4) contributes to the pathogenesis of mouse and human CLL. Blood 2011, 117:862-871. 10.1182/blood-2010-05-284638, 3035078, 21098398.
9. Liu TH, Raval A, Chen SS, Matkovic JJ, Byrd JC, Plass C. CpG island methylation and expression of the secreted frizzled-related protein gene family in chronic lymphocytic leukemia. Cancer Res 2006, 66:653-658. 10.1158/0008-5472.CAN-05-3712, 16423993.
10. Raval A, Lucas DM, Matkovic JJ, Bennett KL, Liyanarachchi S, Young DC, Rassenti L, Kipps TJ, Grever MR, Byrd JC. TWIST2 demonstrates differential methylation in immunoglobulin variable heavy chain mutated and unmutated chronic lymphocytic leukemia. J Clin Oncol 2005, 23:3877-3885. 10.1200/JCO.2005.02.196, 15809452.
11. Chantepie SP, Vaur D, Grunau C, Salaun V, Briand M, Parienti JJ, Heutte N, Cheze S, Roussel M, Gauduchon P, et al. ZAP-70 intron1 DNA methylation status: determination by pyrosequencing in B chronic lymphocytic leukemia. Leuk Res 2010, 34:800-808. 10.1016/j.leukres.2009.10.018, 19944462.
12. Calin GA, Croce CM. MicroRNA signatures in human cancers. Nat Rev Cancer 2006, 6:857-866. 10.1038/nrc1997, 17060945.
13. Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell 2009, 136:215-233. 10.1016/j.cell.2009.01.002, 3794896, 19167326.
14. Chen CZ. MicroRNAs as oncogenes and tumor suppressors. N Engl J Med 2005, 353:1768-1771. 10.1056/NEJMp058190, 16251533.
15. Zhang B, Pan X, Cobb GP, Anderson TA. microRNAs as oncogenes and tumor suppressors. Dev Biol 2007, 302:1-12. 10.1016/j.ydbio.2006.08.028, 16989803.
16. Wong KY, Huang X, Chim CS. DNA methylation of microRNA genes in multiple myeloma. Carcinogenesis 2012, 33:1629-1638. 10.1093/carcin/bgs212, 22715154.
17. Yim RLH, Kwong YL, Wong KY, Chim CS. DNA methylation of tumor suppressive miRNAs in non-Hodgkin's lymphomas. Front Genet 2012, 3:223. 3494017, 23162566.
18. Wang LQ, Liang R, Chim CS. Methylation of tumor suppressor microRNAs: lessons from lymphoid malignancies. Expert Rev Mol Diagn 2012, 12:755-765. 10.1586/erm.12.64, 23153241.
19. Tsai KW, Liao YL, Wu CW, Hu LY, Li SC, Chan WC, Ho MR, Lai CH, Kao HW, Fang WL. Aberrant hypermethylation of miR-9 genes in gastric cancer. Epigenetics 2011, 6:1189-1197. 10.4161/epi.6.10.16535, 3225840, 21931274.
20. Zhang H, Qi M, Li S, Qi T, Mei H, Huang K, Zheng L, Tong Q. microRNA-9 targets matrix metalloproteinase 14 to inhibit invasion, metastasis, and angiogenesis of neuroblastoma cells. Mol Cancer Ther 2012, 11:1454-1466. 10.1158/1535-7163.MCT-12-0001, 22564723.
21. Ma L, Young J, Prabhala H, Pan E, Mestdagh P, Muth D, Teruya-Feldstein J, Reinhardt F, Onder TT, Valastyan S. miR-9, a MYC/MYCN-activated microRNA, regulates E-cadherin and cancer metastasis. Nat Cell Biol 2010, 12:247-256. 2845545, 20173740.
22. Nass D, Rosenwald S, Meiri E, Gilad S, Tabibian-Keissar H, Schlosberg A, Kuker H, Sion-Vardy N, Tobar A, Kharenko O. MiR-92b and miR-9/9* are specifically expressed in brain primary tumors and can be used to differentiate primary from metastatic brain tumors. Brain Pathol 2009, 19:375-383. 10.1111/j.1750-3639.2008.00184.x, 2728890, 18624795.
23. Schraivogel D, Weinmann L, Beier D, Tabatabai G, Eichner A, Zhu JY, Anton M, Sixt M, Weller M, Beier CP. CAMTA1 is a novel tumour suppressor regulated by miR-9/9* in glioblastoma stem cells. EMBO J 2011, 30:4309-4322. 10.1038/emboj.2011.301, 3199389, 21857646.
24. Guo LM, Pu Y, Han Z, Liu T, Li YX, Liu M, Li X, Tang H. MicroRNA-9 inhibits ovarian cancer cell growth through regulation of NF-κB1. FEBS J 2009, 276:5537-5546. 10.1111/j.1742-4658.2009.07237.x, 19702828.
25. Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Döhner H, Hillmen P, Keating MJ, Montserrat E, Rai KR, Kipps TJ. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 2008, 111:5446-5456. 10.1182/blood-2007-06-093906, 2972576, 18216293.
26. Jaffe ES. Pathology and genetics of tumours of haematopoietic and lymphoid tissues 2001, Lyon: LARC Press.
27. Stacchini A, Aragno M, Vallario A, Alfarano A, Circosta P, Gottardi D, Faldella A, Rege-Cambrin G, Thunberg U, Nilsson K. MEC1 and MEC2: two new cell lines derived from B-chronic lymphocytic leukaemia in prolymphocytoid transformation. Leuk Res 1999, 23:127-136. 10.1016/S0145-2126(98)00154-4, 10071128.
28. Wendel-Hansen V, Sällström J, De Campos-Lima P, Kjellström G, Sandlund A, Siegbahn A, Carlsson M, Nilsson K, Rosen A. Epstein-Barr virus (EBV) can immortalize B-cll cells activated by cytokines. Leukemia 1994, 8:476-484.
29. Rosén A, Bergh AC, Gogok P, Evaldsson C, Myhrinder AL, Hellqvist E, Rasul A, Björkholm M, Jansson M, Mansouri L. Lymphoblastoid cell line with B1 cell characteristics established from a chronic lymphocytic leukemia clone by in vitro EBV infection. Oncol Immunol 2012, 1:18-27.
30. Herman JG, Graff JR, Myöhänen S, Nelkin BD, Baylin SB. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA 1996, 93:9821-9826. 10.1073/pnas.93.18.9821, 38513, 8790415.
31. Wong KY, Yim RLH, So CC, Jin DY, Liang R, Chim CS. Epigenetic inactivation of the MIR34B/C in multiple myeloma. Blood 2011, 118:5901-5904. 10.1182/blood-2011-06-361022, 21976676.
32. Livak KJ, Schmittgen TD. Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2 ΔΔ CT Method. Methods 2001, 25:402-408. 10.1006/meth.2001.1262, 11846609.
33. Wong KY, Liang R, So CC, Jin DY, Costello JF, Chim CS. Epigenetic silencing of MIR203 in multiple myeloma. Br J Haematol 2011, 154:569-578. 10.1111/j.1365-2141.2011.08782.x, 21707582.
34. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 1983, 65:55-63. 10.1016/0022-1759(83)90303-4, 6606682.
35. van Engeland M, Ramaekers FC, Schutte B, Reutelingsperger CP. A novel assay to measure loss of plasma membrane asymmetry during apoptosis of adherent cells in culture. Cytometry 1996, 24:131-139. 10.1002/(SICI)1097-0320(19960601)24:2<131::AID-CYTO5>3.0.CO;2-M, 8725662.
36. Lujambio A, Ropero S, Ballestar E, Fraga MF, Cerrato C, Setién F, Casado S, Suarez-Gauthier A, Sanchez-Cespedes M, Gitt A, et al. Genetic unmasking of an epigenetically silenced microRNA in human cancer cells. Cancer Res 2007, 67:1424-1429. 10.1158/0008-5472.CAN-06-4218, 17308079.
37. Baer C, Claus R, Frenzel LP, Zucknick M, Park YJ, Gu L, Weichenhan D, Fischer M, Pallasch CP, Herpel E, et al. Extensive Promoter DNA Hypermethylation and Hypomethylation Is Associated with Aberrant MicroRNA Expression in Chronic Lymphocytic Leukemia. Cancer Res 2012, 72:3775-3785. 10.1158/0008-5472.CAN-12-0803, 22710432.
38. Chim CS, Fung TK, Wong KF, Lau JS, Law M, Liang R. Methylation of INK4 and CIP/KIP families of cyclin-dependent kinase inhibitor in chronic lymphocytic leukaemia in Chinese patients. J Clin Pathol 2006, 59:921-926. 10.1136/jcp.2005.035089, 1860467, 16565223.
39. Dores GM, Anderson WF, Curtis RE, Landgren O, Ostroumova E, Bluhm EC, Rabkin CS, Devesa SS, Linet MS. Chronic lymphocytic leukaemia and small lymphocytic lymphoma: overview of the descriptive epidemiology. Br J Haematol 2007, 139:809-819. 10.1111/j.1365-2141.2007.06856.x, 17941952.
40. Hildebrandt M, Gu J, Lin J, Ye Y, Tan W, Tamboli P, Wood C, Wu X. Hsa-miR-9 methylation status is associated with cancer development and metastatic recurrence in patients with clear cell renal cell carcinoma. Oncogene 2010, 29:5724-5728. 10.1038/onc.2010.305, 20676129.
41. Heller G, Weinzierl M, Noll C, Babinsky V, Ziegler B, Altenberger C, Minichsdorfer C, Lang G, Döme B, End-Pfützenreuter A, et al. Genome-Wide miRNA Expression Profiling Identifies miR-9-3 and miR-193a as Targets for DNA Methylation in Non-Small Cell Lung Cancers. Clin Cancer Res 2012, 18:1619-1629. 10.1158/1078-0432.CCR-11-2450, 22282464.
42. Lujambio A, Calin GA, Villanueva A, Ropero S, Sánchez-Céspedes M, Blanco D, Montuenga LM, Rossi S, Nicoloso MS, Faller WJ, et al. A microRNA DNA methylation signature for human cancer metastasis. Proc Natl Acad Sci USA 2008, 105:13556-13561. 10.1073/pnas.0803055105, 2528872, 18768788.
43. Bandres E, Agirre X, Bitarte N, Ramirez N, Zarate R, Roman-Gomez J, Prosper F, Garcia-Foncillas J. Epigenetic regulation of microRNA expression in colorectal cancer. Int J Cancer 2009, 125:2737-2743. 10.1002/ijc.24638, 19521961.
44. Karin M, Cao Y, Greten FR, Li Z-W. NF-κB in cancer: from innocent bystander to major culprit. Nat Rev Cancer 2002, 2:301-310. 10.1038/nrc780, 12001991.
45. Van Antwerp DJ, Martin SJ, Kafri T, Green DR, Verma IM. Suppression of TNF-α-Induced Apoptosis by NF-κB. Science 1996, 274:787-789. 10.1126/science.274.5288.787, 8864120.
46. Tak PP, Firestein GS. NF-kappaB: a key role in inflammatory diseases. J Clin Invest 2001, 107:7-12. 10.1172/JCI11830, 198552, 11134171.
47. Bazzoni F, Rossato M, Fabbri M, Gaudiosi D, Mirolo M, Mori L, Tamassia N, Mantovani A, Cassatella MA, Locati M. Induction and regulatory function of miR-9 in human monocytes and neutrophils exposed to proinflammatory signals. Proc Natl Acad Sci U S A 2009, 106:5282-5287. 10.1073/pnas.0810909106, 2664036, 19289835.
48. Furman RR, Asgary Z, Mascarenhas JO, Liou H-C, Schattner EJ. Modulation of NF-κB Activity and Apoptosis in Chronic Lymphocytic Leukemia B Cells. J Immunol 2000, 164:2200-2206.
49. Cuni S, Perez-Aciego P, Perez-Chacon G, Vargas JA, Sanchez A, Martin-Saavedra FM, Ballester S, Garcia-Marco J, Jorda J, Durantez A. A sustained activation of PI3K/NF-κB pathway is critical for the survival of chronic lymphocytic leukemia B cells. Leukemia 2004, 18:1391-1400. 10.1038/sj.leu.2403398, 15175625.